HK Stock Market Move | KUAISHOU-W (01024) further increased by nearly 5%, Possible significant increase in the company's revenue for the fiscal year 2026 with the overseas expansion of Ke Ling AI in the new year.
Kuaishou-W(01024) has increased by nearly 5%, with a cumulative increase of over 20% this month. As of the time of writing, it has risen by 4.15%, closing at 77.8 Hong Kong dollars, with a trading volume of 25.22 billion Hong Kong dollars.
KUAISHOU-W (01024) rose nearly 5% again, with a cumulative increase of over 20% this month. As of press time, it rose by 4.15% to HK$77.8, with a turnover of HK$25.22 billion.
On the news front, recently, Kuaishou's AI Ling has sparked a creative trend on overseas social platforms with its "action control" feature, spreading from South Korea to the world, becoming a new hot product for Chinese AI going abroad. According to SensorTower's data, AI Ling's daily income on January 1-3, 2026 increased by 102% compared to December 2025. JPMorgan Chase stated that Kuaishou occupies a leading position in the generative AI critical race, and is one of the most underestimated AI stocks globally.
Goldman Sachs stated that Kuaishou's AI Ling, following a model upgrade and new feature launches in December last year, is expected to drive user recognition and revenue expansion in overseas markets, potentially boosting Kuaishou's revenue expectations for the fiscal year 2026 and boosting its stock price. Analysts in the report forecast AI Ling's revenue to exceed $140 million in 2025 and around $230-240 million in 2026.
Related Articles

RAFFLES INTERIOR (01376) will be suspended briefly starting from the afternoon of January 12th.

CLOVER BIO-B (02197) initiates phase 2 clinical trial for RSV - hMPV - PIV3 respiratory combined vaccine candidate product.

India plans to introduce the world's strictest mobile phone security regulations, requiring Apple Inc. (AAPL.US) and Samsung to open source code.
RAFFLES INTERIOR (01376) will be suspended briefly starting from the afternoon of January 12th.

CLOVER BIO-B (02197) initiates phase 2 clinical trial for RSV - hMPV - PIV3 respiratory combined vaccine candidate product.

India plans to introduce the world's strictest mobile phone security regulations, requiring Apple Inc. (AAPL.US) and Samsung to open source code.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


